Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...
A chemotherapy-free regimen significantly improved outcomes compared with standard therapy for newly diagnosed Ph+ acute ...
At some point during 2 years of chemotherapy, 30% of families reported household material hardship and 31.5% had income loss ...
"We just have to keep going.... Because he deserves nothing but the best, nothing but positivity and good vibes and ...
Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...
Nearly a third of families with children receiving chemotherapy for acute lymphoblastic leukemia (ALL)—the most common ...
In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received ...
A study published in the NEJM looks at universal base-edited CAR7 T cells for T-cell acute lymphoblastic leukemia. Dr Rubina Ahmed, Director of Research, Policy and Services, Blood Cancer UK, said: ...
China is making significant strides in CAR-T innovation. Recently, Chongqing Precision Biotech received approval for Priligy ...
News Medical on MSN
Genome-edited immune cell therapy shows promise for treating aggressive blood cancer
A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) ...
Some younger patients with B-cell acute lymphoblastic leukemia may be able to avoid total body irradiation conditioning prior ...
About one-third of families with a child undergoing treatment for acute lymphoblastic leukemia experienced catastrophic income loss during therapy, with many developing new material hardships over the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback